Table 2.

Course of disease in patients with COVID-19 and seasonal influenza.

	COVID-19 (n = 166)	Influenza (n = 255)	P value
Mean length of stay—days (SD)a	25.9 (26.6)	17.2 (21.0)	0.002
Nosocomial infections, no. (%)	24 (14.5)	27 (10.6)	0.29
Transferrals, no. (%)	27 (16.3)	24 (9.4)	0.046
Outpatient treatment, no. (%)	19 (11.4)	76 (29.8)	< 0.001
Admission to ICU, no. (%)	70 (42.2)	51 (20.0)	< 0.001
Oxygen therapy
Total, no. (%)	101 (60.8)	103 (40.4)	< 0.001
Low-flow oxygen, no. (%)	41 (24.7)	57 (22.4)	0.64
Ventilation (total), no. (%)	60 (36.1)	46 (18.0)	< 0.001
Ventilation (HFNC), no. (%)	8 (4.8)	2 (0.8)	0.02
Ventilation (NIV), no. (%)	0 (0)	12 (4.7)	0.004
Ventilation (Invasive), no. (%)	52 (31.3)	32 (12.5)	< 0.001
Vasopressor therapy, no. (%)	56 (33.7)	36 (14.1)	< 0.001
Renal replacement therapy, no. (%)	35 (21.1)	25 (9.8)	0.002
ECMO, no. (%)	12 (7.2)	11 (4.3)	0.27
Antibiotic treatment, no. (%)	172 (67.5)	112 (67.5)	0.83
Antiviral treatment
Total, no. (%)	27 (16.3)	62 (24.3)	0.05
Oseltamivir, no. (%)		62 (24.3)
Lopinavir/ritonavir, no. (%)	9 (5.4)
Remdesivir, no. (%)	9 (5.4)
Hydroxychloroquine, no. (%)	8 (4.8)
Immunotherapy
Total, no. (%)	15 (9.0)
Convalescent plasma, no. (%)	4 (2.4)
Tocilizumab, no. (%)	3 (1.8)
Adrecizumab, no. (%)	8 (4.8)
Deceased, no. (%)	26 (15.9)	23 (9.0)	0.04

COVID-19 coronavirus disease 2019, SD standard deviation, ICU intensive care unit, ECMO extracorporeal membrane oxygenation, HFNC high-flow nasal oxygen, NIV non-invasive ventilation.

^aOnly hospitalized COVID-19 and influenza patients were included in the analysis on length of stay. Two COVID-19 patients with the need for mechanical ventilation were still hospitalized and were thus not included in the analysis of mortality and mean length of hospital stay.